Samsung Bioepis targets Stelara market
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.07.01 05:36:34
°¡³ª´Ù¶ó
0
Will release its products in July... Knocking on the door with its price competitiveness
Company sells more than half of all its products directly... will become a test of the company¡¯s marketing capabilities
Samsung Bioepis is seeking to target the Stelara (Ustekinumab) market by directly marketing its Stelara biosimilar Epyztek in Korea.
The company is adding Epyztek to the list of autoimmune disease treatments it has been selling directly since March, a strategy that is expected to strengthen its marketing capabilities while increasing profitability.
¡ãA view of the Samsung Bioepis building in Songdo.
Samsung Bioepis will launch Epyztek, an autoimmune disease treatment, in the Korean market in July. Epyztek is a biosimilar of Stelara, Janssen¡¯s treatment for autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Epyztek was approved by the Ministry of Food and Drug Safet
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)